Scientists test novel drug duo to reboot immune system against tough cancers

NCT ID NCT05082259

Summary

This is an early-stage study to find a safe dose and see if a new drug combination can help the immune system fight advanced cancers. It will test the experimental drug ASTX660 together with the immunotherapy pembrolizumab in up to 61 adults with solid tumors that have stopped responding to standard treatments. The main goals are to check the safety of the combination and see if it shows any early signs of shrinking tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cambridge University Hospitals NHS Trust

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Royal Marden NHS Foundation Trust - Drug Development Unit

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

    Contact Phone: •••-•••-••••

  • The Royal Marsden NHS Foundation Trust - Breast Unit

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.